Adjuvant anti-CDK thwarts early recurrence of breast cancer

[ad_1] The inclusion of a CDK4 / 6 inhibitor in adjuvant therapy significantly increased invasive disease free survival (iDFS) in hormone receptor (HR) positive early high-risk breast cancer patients, a large randomized trial showed. The risk of iDFS decreased by 25.3% with the addition of abemaciclib (Verzenio) to standard endocrine …

Read More »